golimumab,guselkumab
janssen
['simponi', 'tremfya']
#news- #simponi + t#remfya was administered as induction treatment for 12 weeks, followed by maintenance treatment with tremfya resulted in higher clinical remission of 47.9% at week 38 versus tremfya (31%) or simponi monotherapy (20.8%) #ueg22 #uegweek22
iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma